Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma, Cutaneous Malignant × Dacarbazine × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 74 Neoplasm Metastasis 11 Uveal Melanoma 7 Skin Neoplasms 6 Neoplasms 5 Small Cell Lung Carcinoma 1 Skin Diseases 1 Sarcoma 1 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Parathyroid Neoplasms 1 Oligodendroglioma 1 Melanoma, Cutaneous Malignant 1 Melanoma Neoplasms 1 Lung Neoplasms 1 Kidney Neoplasms 1 Gliosarcoma 1 Glioma, Subependymal 1 Glioma 1 Glioblastoma 1 Ependymoma 1 Colonic Neoplasms 1 Carcinoma 1 Carcinoid Tumor 1 Breast Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1 Advanced Melanoma 1

Interventions

pembrolizumab 3 Paclitaxel 2 relatlimab 1 nintedanib 1 lifileucel 1 dabrafenib 1 Vitamin D 1 Temozolomide 1 Surveys and Questionnaires 1 Opdualag 1 Nivolumab 1 Microarray Analysis 1 Ipilimumab 1 Genetic Testing 1 Gene Expression Profiling 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Biopsy 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06743126 2026-04-13

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡